| Literature DB >> 21394251 |
B M Gurupadayya1, M Gopal, B Padmashali, Y N Manohara.
Abstract
VariousEntities:
Keywords: Benzothiazole; azetidinones; pharmacological activity; thiazolidinones
Year: 2008 PMID: 21394251 PMCID: PMC3038279 DOI: 10.4103/0250-474X.45393
Source DB: PubMed Journal: Indian J Pharm Sci ISSN: 0250-474X Impact factor: 0.975
Scheme 1Synthetic scheme of Schiff's bases, azetidine-2-ones and thiazolidin-4-ones
R= C6H5, C6H4-4-OCH3, C6H4-2-OH, C6H4-3-OCH3, C6H4-4-N(CH3)2, C6H4-2-NO2, C6H4-3Cl and C4H3O (2-furyl). R' = H, Cl and C6H5.
PHYSICAL DATA OF THE SYNTHESIZED COMPOUNDS
| Compd No | R | R1 | Mp (°) | Yield (%) | Mol. formula |
|---|---|---|---|---|---|
| 2a | - | - | 165 | 78 | C14H8ClFN2S |
| 2b | - | - | 160 | 76 | C15H10ClFN2OS |
| 2c | - | - | 175 | 81 | C14H7ClFN2OS |
| 2d | - | - | 155 | 69 | C15H10ClFN2O2S |
| 2e | - | - | 180 | 75 | C16H13ClFN3S |
| 2f | - | - | 168 | 72 | C14H7ClFN3O2S |
| 2g | - | - | 170 | 68 | C14H7Cl2FN2S |
| 2h | - | - | 198 | 70 | C12H6ClFN2OS |
| 3a | C6H5 | H | 188 | 50 | C16H10ClFN2OS |
| 3b | C6H4 -4-OCH3 | H | 185 | 63 | C17H12ClFN2O2S |
| 3c | C6H4-2-OH | H | 190 | 58 | C16H10ClFN2O2S |
| 3d | C6H3-4-OH, 3-OCH3 | H | 170 | 63 | C17H12ClFN2O3S |
| 3e | C6H4-4-N(CH3)2 | H | 195 | 70 | C18H15ClFN3OS |
| 3f | C6H4-2-NO2 | H | 179 | 80 | C16H9ClFN3O3S |
| 3g | C6H4-3-Cl | H | 180 | 73 | C16H9Cl2FN2OS |
| 3h | C4H3O (2-furyl) | H | 205 | 68 | C15H8ClFN2O2S |
| 3i | C6H5 | Cl | 150 | 72 | C15H9ClFN2OS |
| 3j | C6H4-4-OCH3 | Cl | 200 | 69 | C15H11Cl2FN2OS |
| 3k | C6H4-2-OH | Cl | 194 | 55 | C16H9Cl2FN2O2S |
| 3l | C6H3-4-OH, 3-OCH3 | Cl | 187 | 62 | C17H11Cl2FN2O3S |
| 3m | C6H4-4-N(CH3)2 | Cl | 198 | 65 | C18H14Cl2FN3OS |
| 3n | C6H4-2-NO2 | Cl | 202 | 71 | C16H8Cl2FN3OS |
| 3o | C6H4-3-Cl | Cl | 170 | 82 | C16H8Cl3FN2OS |
| 3p | C4H3O (2-furyl) | Cl | 210 | 72 | C14H7Cl2FN2O2S |
| 3q | C6H5 | C6H5 | 215 | 82 | C22H14ClFN2O2S |
| 3r | C6H4-4-OCH3 | C6H5 | 216 | 73 | C23H16Cl2FN2O2S |
| 3s | C6H4-2-OH | C6H5 | 210 | 54 | C22H16ClFN2O3S |
| 3t | C6H3-4-OH, 3-OCH3 | C6H5 | 235 | 63 | C22H16ClFN2O3 S |
| 3u | C6H4-4-N(CH3)2 | C6H5 | 208 | 68 | C24H19ClFN3O3S |
| 3v | C6H4-2-NO2 | C6H5 | 193 | 75 | C22H13ClFN3O3S |
| 3w | C6H4-3-Cl | C6H5 | 218 | 70 | C22H13Cl2FN2OS |
| 3x | C4H3O (2-furyl) | C6H5 | 219 | 73 | C20H12ClFN2O2S |
| 4a | C6H5 | - | 191 | 82 | C16H10ClFN2OS2 |
| 4b | C6H4-4-OCH3 | - | 118 | 85 | C17H12ClFN2O2S2 |
| 4c | C6H4-2-OH | - | 180 | 80 | C16H9ClFN2O2S2 |
| 4d | C6H3-4-OH, 3-OCH3 | - | 157 | 84 | C17H12ClFN2O3S2 |
| 4e | C6H4-4-N(CH3)2 | - | 142 | 78 | C18H15ClFN3OS2 |
| 4f | C6H4-2-NO2 | - | 175 | 74 | C16H9ClFN3OS2 |
| 4g | C6H4-3-Cl | - | 170 | 70 | C16H9Cl2FN2OS2 |
| 4h | C4H3O (2-furyl) | - | 186 | 65 | C14H8ClFN2O2S2 |
C, H, N and S are within the limit of ± 0.3%
RESULTS OF ANTIINFLAMMATORY ACTIVITY OF THE SYNTHESIZED COMPOUNDS
| Compound No. | Paw volumes ±SEM and% reduction | |||||
|---|---|---|---|---|---|---|
| 1 h | 2 h | 3 h | ||||
| Mean±SEM | %RPEV | Mean±SEM | %RPEV | Mean±SEM | %RPEV | |
| 3a | 1.50±0.07 | 14.60 | 1.74±0.07 | 17.14 | 1.87±0.06 | 22.08 |
| 3c | 1.43±0.03 | 19.66 | 1.53±0.05 | 27.14 | 1.70±0.04 | 29.16 |
| 3f | 1.40±0.05 | 21.34 | 1.45±0.05 | 30.95 | 1.63±0.04 | 32.08 |
| 3i | 1.42±0.03 | 20.22 | 1.57±0.11 | 25.23 | 1.63±0.10 | 32.08 |
| 3k | 1.38±0.05 | 22.47 | 1.40±0.06 | 33.33 | 1.43±0.05 | 40.41 |
| 3n | 1.32±0.07 | 25.84 | 1.35±0.05 | 35.71 | 1.35±0.04 | 43.75 |
| 3q | 1.50±0.04 | 15.73 | 1.78±0.05 | 15.23 | 1.90±0.02 | 20.83 |
| 3s | 1.38±0.05 | 22.47 | 1.70±0.05 | 14.04 | 1.80±0.05 | 25.00 |
| 3v | 1.30±0.03 | 26.96 | 1.65±0.03 | 21.42 | 1.75±0.06 | 27.08 |
| 4a | 1.48±0.04 | 22.00 | 1.57±0.05 | 25.23 | 1.65±0.06 | 31.25 |
| 4c | 1.45±0.04 | 18.50 | 1.53±0.04 | 27.14 | 1.63±0.06 | 32.08 |
| 4f | 1.28±0.03 | 28.08 | 1.42±0.06 | 32.38 | 1.48±0.04 | 38.30 |
| Control | 1.78±0.05 | - | 2.10±0.05 | - | 2.4±0.03 | - |
| Diclofenac Sodium | 0.99±0.05 | 43.24 | 1.11±0.03 | 46.00 | 1.11±0.05 | 54.00 |
RPEV is reduction in paw edema volume
Indicates significant difference at p<0.001 when compared to control
RESULTS OF ANALGESIC ACTIVITY OF THE SYNTHESIZED COMPOUNDS
| Compound No. | ABRT in sec | ABRT in sec after treatment | |||
|---|---|---|---|---|---|
| Pre treatment ‘0’ min | 15 min | 30 min | 45 min | 60 min | |
| 3a | 3.60±0.08 | 4.5±0.06 | 6.53±0.04 | 7.03±0.13 | 11.20 ±0.2 |
| 3c | 3.80±0.02 | 4.5±0.06 | 7.05±0.08 | 11.40±0.2 | 11.40 ±0.2 |
| 3f | 3.60±0.02 | 4.62±0.10 | 4.67±0.06 | 5.50±0.14 | 5.30±0.03 |
| 3i | 3.20±0.04 | 5.5±0.22 | 5.5±0.22 | 4.4±0.20 | 3.40±0.37 |
| 3k | 3.40±0.10 | 3.83±0.31 | 6.83±0.48 | 6.00±0.37 | 6.50±0.22 |
| 3n | 2.62±0.04 | 2.67±0.21 | 3.33±0.21 | 4.67±0.21 | 4.00± 0.37 |
| 3q | 3.60±0.10 | 4.17±0.31 | 5.17±0.31 | 8.0±0.26 | 9.83±0.31 |
| 3s | 3.20±0.15 | 4.00±0.26 | 5.5±0.34 | 6.17±0.31 | 6.67±0.21 |
| 3v | 3.50±0.02 | 5.33±0.33 | 8.83±0.78 | 5.67±0.21 | 5.33±0.21 |
| 4a | 3.10±0.06 | 7.17±0.48 | 11.17±0.40 | 10.67±0.5 | 9.67±0.21 |
| 4c | 3.60±0.06 | 6.33±0.80 | 7.76±0.04 | 10.33±0.12 | 9.25±0.08 |
| 4f | 3.60±0.20 | 3.67±0.21 | 3.83±0.31 | 4.33±0.22 | 4.33±0.42 |
| Control | 3.60±0.06 | 3.60±0.10 | 3.50±0.15 | 3.60±0.15 | 3.40±0.06 |
| PentazocineHCl | 3.60±0.08 | 4.93±0.18 | 8.90±0.15 | 10.10±0.2 | 12.50±0.1 |
ABRT: Average Basal Reaction Time
Indicates significant difference at p<0.001 when compared to control
RESULTS OF CNS DEPRESSANT ACTIVITY OF THE SYNTHESIZED COMPOUNDS
| Compound | Before drug (Mean±SEM) | After drug (Mean±SEM) | CNS depressant activity (%) | ||
|---|---|---|---|---|---|
| 30 min | 60 min | 30 min | 60 min | ||
| 3a | 835.91±03.63 | 438.00±07.53 | 621.50±09.45 | 46.50 | 23.60 |
| 3c | 830.90±03.63 | 113.17±07.00 | 354.33±04.12 | 86.20 | 56.40 |
| 3f | 804.65±02.60 | 272.33±14.55 | 503.83±04.94 | 67.00 | 38.00 |
| 3i | 877.65±02.50 | 324.17±05.30 | 386.83±06.43 | 60.40 | 52.50 |
| 3k | 915.63±02.30 | 384.17±14.28 | 453.33±13.24 | 53.10 | 44.30 |
| 3n | 858.13±05.36 | 360.50±18.36 | 466.17±12.23 | 56.00 | 42.70 |
| 3q | 766.18±07.21 | 477.17±07.82 | 655.83±12.08 | 41.70 | 19.30 |
| 3s | 811.55±02.20 | 252.50±16.80 | 347.00±17.80 | 69.20 | 57.30 |
| 3v | 823.37±01.45 | 608.33±02.23 | 725.33±02.94 | 25.70 | 10.80 |
| 4a | 811.50±02.00 | 624.00±07.13 | 733.50±03.45 | 23.80 | 09.80 |
| 4c | 825.53±02.14 | 215.00±15.92 | 405.00±08.37 | 73.70 | 50.20 |
| 4f | 815.49±01.93 | 217.33±08.73 | 385.33±12.12 | 73.50 52.60 | |
| Control | 820.23±06.88 | 818.67±05.93 | 813.17±07.01 | - | - |
| Diazepam | 840.64±09.26 | 82.17±04.04 | 112.50±06.55 | 90.00 | 86.20 |
Indicates significant difference at p<0.001 when compared to control
RESULTS OF SKELETAL MUSCLE RELAXANT ACTIVITY OF SYNTHESIZED COMPOUNDS
| Compound | Fall of time | % Decrease in time | |
|---|---|---|---|
| Before the drug treatment | After the drug treatment | ||
| 3a | 43.00±1.37 | 15.50±0.12 | 64.00 |
| 3c | 23.50±1.52 | 14.17±1.01 | 39.70 |
| 3f | 26.17±1.19 | 16.00±0.68 | 38.86 |
| 3i | 38.50±1.38 | 22.50±1.38 | 41.55 |
| 3k | 26.83±1.47 | 20.67±0.95 | 22.95 |
| 3n | 34.83±1.35 | 16.67±0.80 | 52.13 |
| 3q | 44.00±1.65 | 33.67±0.33 | 23.50 |
| 3s | 35.67±1.25 | 30.62±1.01 | 14.15 |
| 3v | 42.33±0.76 | 38.17±1.28 | 09.30 |
| 4a | 32.67±0.84 | 15.33±1.05 | 53.07 |
| 4c | 26.17±1.08 | 10.83±1.38 | 58.61 |
| 4f | 30.17±0.95 | 12.00±1.10 | 60.22 |
| Control | 34.83±1.25 | 34.67±1.33 | - |
| Diazepam | 28.32 ± 0.20 | 5.75 ± 0.07 | 79.69 |
Indicates significant difference at p<0.001 when compared to control